MX2014003186A - Formulaciones farmacéuticas resistentes a la manipulación. - Google Patents
Formulaciones farmacéuticas resistentes a la manipulación.Info
- Publication number
- MX2014003186A MX2014003186A MX2014003186A MX2014003186A MX2014003186A MX 2014003186 A MX2014003186 A MX 2014003186A MX 2014003186 A MX2014003186 A MX 2014003186A MX 2014003186 A MX2014003186 A MX 2014003186A MX 2014003186 A MX2014003186 A MX 2014003186A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulations
- tamper resistant
- resistant pharmaceutical
- dosage form
- active agent
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003349 gelling agent Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
Abstract
En ciertas modalidades se describe una forma de dosis oral que comprende una pluralidad de partículas, cada partícula comprende un núcleo comprimido que comprende: (i) un agente activo susceptible a abuso y (ii) un agente gelificante; en donde la pluralidad de partículas contiene una cantidad terapéutica o profilácticamente efectiva del agente activo; y en donde la viscosidad de la forma de dosis mezclada con de aproximadamente 0.5 a aproximadamente 10 ml de un líquido acuoso es inadecuada para administración parenteral o nasal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161535743P | 2011-09-16 | 2011-09-16 | |
PCT/IB2012/001914 WO2013038267A1 (en) | 2011-09-16 | 2012-09-14 | Tamper resistant pharmaceutical formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014003186A true MX2014003186A (es) | 2015-10-12 |
MX355478B MX355478B (es) | 2018-04-19 |
Family
ID=47018275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014003186A MX355478B (es) | 2011-09-16 | 2012-09-14 | Formulaciones farmacéuticas resistentes a la manipulación. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20140341984A1 (es) |
EP (1) | EP2755640B1 (es) |
JP (1) | JP6110384B2 (es) |
AU (1) | AU2012310250B2 (es) |
CA (1) | CA2847611A1 (es) |
ES (1) | ES2641437T3 (es) |
IL (1) | IL231485A (es) |
MX (1) | MX355478B (es) |
WO (1) | WO2013038267A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
EP2301526B1 (en) | 2003-03-26 | 2016-03-23 | Egalet Ltd. | Morphine controlled release system |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
NZ603579A (en) | 2009-06-24 | 2014-02-28 | Egalet Ltd | Controlled release formulations |
UY34651A (es) * | 2012-03-02 | 2013-09-30 | Rhodes Pharmaceuticals Lp | ?formas de dosificación de liberación inmediata resistentes a la manipulación, procesos para prepararlas, métodos y usos de las mismas?.. |
RS57913B1 (sr) * | 2012-04-18 | 2019-01-31 | Gruenenthal Gmbh | Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze |
EA201590165A1 (ru) | 2012-07-06 | 2015-08-31 | Эгалет Лтд. | Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения |
AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
US20210205295A1 (en) * | 2017-10-20 | 2021-07-08 | Purdue Pharma L.P. | Pharmaceutical dosage forms |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
MXPA04001206A (es) * | 2001-08-06 | 2004-07-08 | Euro Celtique Sa | Composiciones y metodos para prevenir el abuso de opioides. |
DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
NZ547284A (en) * | 2003-10-31 | 2009-12-24 | Hexal Ag | Pharmaceutical agent-containing formulation comprising a coating of a film forming polymer |
WO2006079550A2 (en) * | 2005-01-28 | 2006-08-03 | Euro-Celtique S.A. | Alcohol resistant dosage forms |
TWI365880B (en) | 2004-03-30 | 2012-06-11 | Euro Celtique Sa | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp |
US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20090022798A1 (en) * | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
US9023400B2 (en) * | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
SA07280459B1 (ar) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
PL2079446T3 (pl) * | 2007-08-21 | 2012-04-30 | Teva Pharma | Preparat paliperidonu o przedłużonym uwalnianiu |
GB0909680D0 (en) * | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
CN103370058A (zh) * | 2010-12-22 | 2013-10-23 | 普渡制药公司 | 包覆的抗篡改控制释放剂型 |
-
2012
- 2012-09-14 ES ES12813950.8T patent/ES2641437T3/es active Active
- 2012-09-14 US US14/344,279 patent/US20140341984A1/en not_active Abandoned
- 2012-09-14 AU AU2012310250A patent/AU2012310250B2/en active Active
- 2012-09-14 JP JP2014530331A patent/JP6110384B2/ja active Active
- 2012-09-14 MX MX2014003186A patent/MX355478B/es active IP Right Grant
- 2012-09-14 CA CA2847611A patent/CA2847611A1/en not_active Abandoned
- 2012-09-14 EP EP12813950.8A patent/EP2755640B1/en active Active
- 2012-09-14 WO PCT/IB2012/001914 patent/WO2013038267A1/en active Application Filing
-
2014
- 2014-03-12 IL IL231485A patent/IL231485A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP2755640B1 (en) | 2017-07-26 |
MX355478B (es) | 2018-04-19 |
AU2012310250A1 (en) | 2013-05-02 |
WO2013038267A1 (en) | 2013-03-21 |
AU2012310250B2 (en) | 2016-03-03 |
US20140341984A1 (en) | 2014-11-20 |
IL231485A (en) | 2017-03-30 |
WO2013038267A8 (en) | 2014-04-24 |
CA2847611A1 (en) | 2013-03-21 |
JP2014526497A (ja) | 2014-10-06 |
IL231485A0 (en) | 2014-04-30 |
JP6110384B2 (ja) | 2017-04-05 |
ES2641437T3 (es) | 2017-11-10 |
EP2755640A1 (en) | 2014-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX355478B (es) | Formulaciones farmacéuticas resistentes a la manipulación. | |
MX2014003192A (es) | Formulaciones de liberación inmediata resistentes a alteración. | |
NZ629468A (en) | Tamper resistant immediate release formulations | |
WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
MX2009004871A (es) | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. | |
PH12015501756A1 (en) | Tamper resistant pharmaceutical formulations | |
MY162175A (en) | Aqueous drug delivery system | |
EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
RS52831B (en) | THIN BUPRENORPHINE TILES FOR DRUG REPLACEMENT THERAPY | |
WO2007134292A3 (en) | Treprostinil administration using a metered dose inhaler | |
TN2015000326A1 (en) | Tamper resistant pharmaceutical formulations | |
MX368774B (es) | Nueva dosificación y formulación. | |
MX335944B (es) | Composiciones que comprenden sulfato de salbutamol. | |
MX336225B (es) | Composiciones que comprenden sulfato de salbutamol. | |
PH12014501408A1 (en) | Immediate release multi unit pellet system | |
DE602008006700D1 (es) | ||
EP4233874A3 (en) | Acetylsalicylic acid for reducing the risk of a thromboembolic event | |
PH12014502619A1 (en) | Novel dosage and formulation | |
PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
AU2014226192A8 (en) | Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles | |
UA80243U (ru) | Система доставки лекарств | |
IN2013MU03390A (es) | ||
UA97524C2 (ru) | Лекарственный препарат противосудорожного действия топиромата в форме таблеток и его кристаллический состав |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |